Arbitrage Is Not a Feature.
It’s a Signal of Failure.
In Arbitrage Is Not a Feature.every functioning market, arbitrage is temporary.
Capital spots a price gap, rushes in to exploit it, and in doing so, closes it. Prices converge. The free profit disappears. That process is not a flaw. It is the mechanism by which markets become efficient.
Now look at healthcare.
The same procedure. The same physician. The same patient. Generating 2 to 5x different payments based entirely on where it is billed.
Not because of cost differences. Not because of quality differences. Because of administrative constructs: site of service, ownership structure, and fee schedule design.
That is not temporary arbitrage.
That is permanent arbitrage.
And permanent arbitrage means one thing in economics: the price formation mechanism is broken.
It breaks in two specific ways.
First, no real price transparency. Buyers cannot observe prices before the transaction.
Negotiated rates are hidden, cash prices are inconsistent, and transparency compliance is mostly theater.
Without visible prices, arbitrage cannot be competed away. Second, the system actively prevents convergence.
Multiple fee schedules, geographic adjustments, and site-based billing rules do not just allow price differences.
They protect them.
Once arbitrage becomes structural, capital stops flowing toward efficiency.
It flows toward yield.
Health systems do not reduce costs to improve margins. They acquire sites of care that bill at higher rates.
They shift volume into higher-paying settings. They optimize coding, not care delivery. That is not competition.
That is a strategy built entirely on regulatory arbitrage, and it works precisely because the spread is protected.
This is a capital allocation problem.
When arbitrage is permanent and structural, it functions like a bond with a government-guaranteed coupon.
Capital crowds in.
Innovation starves.
The most sophisticated operators in the market are not building better care models. They are building better billing architectures.
Compare that to what a functioning market in medical services would look like.
Visible prices.
Consistent payment for the same service regardless of where it is delivered.
Facilities and physicians competing on efficiency, access, and outcomes rather than on billing jurisdiction.
From that baseline, the next layer becomes possible: standardized bundles, forward contracts on surgical volume, even exchange-traded medical services with the same pricing discipline as any other commodity.
That market is not science fiction. It is simply incompatible with protected arbitrage.
So what actually fixes this?
Not antitrust. Not adding regulatory complexity on top of existing regulatory complexity.
Two structural changes.
Site neutral payments eliminate artificial price dispersion. If the same service pays the same regardless of location, the spread collapses. The yield play disappears. Capital has to compete on efficiency because that is the only thing left.
Real price transparency forces convergence. When buyers can compare prices, providers must justify differentials with value rather than opacity. Arbitrage shrinks because the information asymmetry that sustains it no longer exists.
These two changes do not reinvent the system. They allow a market to exist.
And once a market exists, arbitrage does what it was always supposed to do.
It disappears.
In its place: actual competition. Actual price signals. Actual capital formation around efficiency rather than yield extraction.
Healthcare has not been broken for three decades. It has been optimized, deliberately and profitably, around a pricing structure that rewards positioning over performance.
The fix is not complicated.
Let prices converge.
-Rojas out
